Risk of lung cancer decreases drastically within 5 years of quitting smoking

Risk of lung cancer decreases drastically within 5 years of quitting smoking. Lung cancer treatment in India, best doctors, hospitals & total cost of treatment.

Share This Post

 

Latest research and analysis of the landmark Framingham Heart Study by researchers at Vanderbilt University Medical Center suggest that risk of lung cancer reduces drastically within 5 years of quitting smoking. World No Tobacco Day was observed through out the world looking at the adverse effects of smoking. Notably is the fact that smoking effects almost all 100 types of cancer in humans. The study, which is supported by the National Heart, Lung, and Blood Institute, helped establish high blood pressure and high cholesterol as key risk factors for cardiovascular disease. But it also tracked cancer outcomes.

Stop smoking to prevent cancer
The current study looked at 8,907 participants who had been followed for 25 to 34 years. During this period, 284 lung cancers were diagnosed, nearly 93 percent of which occurred among heavy smokers, those who had smoked at least a pack of cigarettes a day for 21 years or more. Five years after quitting, the risk of developing lung cancer in former heavy smokers dropped by 39 percent compared to current smokers, and continued to fall as time went on. Yet even 25 years after quitting, their lung-cancer risk remained over threefold higher compared to people who had never smoked.

 

Hope this new study motivates people to quit smoking as soon as possible. Lets come together and take a pledge on this World No Tobacco Day to educate smokers on the ill effects of smoking.

 

For details on cancer treatment and second opinion, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

 

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/